Universität zu Köln

Journal Article

Abruzzo, Lynne, Herling, Carmen, Coombes, Kevin, Benner, Axel, Bloehdorn, Johannes, Barron, Lynn L., Abrams, Zachary, Majewski, Tadeusz, Bondaruk, Jolanta, Bahlo, Jasmin, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Czerniak, Bogdan, Oakes, Christopher, Ferrajoli, Alessandra and Keating, Michael (2020). Gene expression signatures predict time-to-progression after front-line chemoimmunotherapy for CLL. Leuk. Lymphoma, 61. S. 7 - 9. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Brown, Jennifer R., Eichhorst, Barbara, Hillmen, Peter, Lamanna, Nicole, O'Brien, Susan M., Tam, Constantine S., Qiu, Lugui, Kazmierczak, Maciej, Jurczak, Wojciech, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda L., Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte A., Salmi, Tommi, Wang, Megan (Der Yu), Fu, Lina, Li, Jessica, Wu, Kenneth, Cohen, Aileen and Shadman, Mazyar (2022). Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study. Blood, 140. S. 19 - 24. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Brown, Jennifer. R. R., Eichhorst, Barbara, Hillmen, Peter, Jurczak, Wojciech, Kazmierczak, Maciej, Lamanna, Nicole, O'Brien, Susan. M. M., Tam, Constantine. S. S., Qiu, Lugui, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda, Ferrajoli, Alessandra, Ganly, Peter. S. S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte. A. A., Salmi, Tommi, Wang, Megan-Der-Yu, Fu, Lina., Li, Jessica, Wu, Kenneth, Cohen, Aileen and Shadman, Mazyar . Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N. Engl. J. Med.. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Herling, Carmen D., Coombes, Kevin R., Benner, Axel, Bloehdorn, Johannes, Barron, Lynn L., Abrams, Zachary B., Majewski, Tadeusz, Bondaruk, Jolanta E., Bahlo, Jasmin, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Czerniak, Bogdan A., Oakes, Christopher C., Ferrajoli, Alessandra, Keating, Michael J. and Abruzzo, Lynne V. (2019). Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncol., 20 (11). S. 1576 - 1587. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Wendtner, Clemens, Hillmen, Peter, Mahadevan, Daruka, Stilgenbauer, Stephan, Uharek, Lutz, Coutre, Steven, Frankfurt, Olga, Bloor, Adrian, Bosch, Francesc ORCID: 0000-0001-9241-2886, Furman, Richard R., Kimby, Eva, Gribben, John G., Gobbi, Marco, Dreisbach, Luke, Hurd, David Duane, Sekeres, Mikkael A., Ferrajoli, Alessandra, Shah, Sheetal, Zhang, Jennie, de Parseval, Laure Moutouh and Chanan-Khan, Asher A. (2010). Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). Blood, 116 (21). S. 591 - 593. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971